Related references
Note: Only part of the references are listed.[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
Steffie M. B. Peters et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
Swayamjeet Satapathy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.
Ken Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study.
Masatoshi Hotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
Christiane Schuchardt et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Phillip H. Kuo et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review
Amit Nautiyal et al.
NUCLEAR MEDICINE COMMUNICATIONS (2022)
Early PSA Change after [177Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
Felix Kind et al.
CANCERS (2022)
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)
Fadi Khreish et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
Steffie M. B. Peters et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Katarina Sjogreen Gleisner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
Michael Mix et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Benedikt Feuerecker et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
Masatoshi Hotta et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis
Mohammad S. Sadaghiani et al.
PROSTATE (2022)
Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
Sonia Mahajan et al.
TRANSLATIONAL ONCOLOGY (2022)
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review
Isabel Heidegger et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy
Kamaldeep et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2021)
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
Hojjat Ahmadzadehfar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
Fadi Khreish et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
Mark Konijnenberg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617
Elahe Mahmoudi et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy
Jeremie Calais et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy
Murat Tuncel et al.
ANNALS OF NUCLEAR MEDICINE (2021)
Nuclear medicine theranostics comes of age
Ken Herrmann et al.
LANCET ONCOLOGY (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
Julia Brosch-Lenz et al.
EJNMMI PHYSICS (2021)
Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy
Friederike Voelter et al.
DIAGNOSTICS (2021)
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study
Bastiaan M. Prive et al.
CLINICAL CANCER RESEARCH (2021)
A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
Mohammad S. Sadaghiani et al.
EUROPEAN UROLOGY (2021)
Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution
Annaleis Tatkovic et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2021)
Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
Kerstin Michalski et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
Madhav Prasad Yadav et al.
PLOS ONE (2021)
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
Vikas Prasad et al.
FRONTIERS IN ONCOLOGY (2021)
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Florian Rosar et al.
EJNMMI PHYSICS (2021)
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
Murali Kesavan et al.
DIAGNOSTICS (2021)
Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand
Kotchakorn Chatachot et al.
ANNALS OF NUCLEAR MEDICINE (2021)
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
Jeremie Calais et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita et al.
LANCET ONCOLOGY (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability
Sonam Suman et al.
PROSTATE (2021)
Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer
Cigdem Soydal et al.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Streamlined Schemes for Dosimetry of Lu-177-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
Jens Kurth et al.
CANCERS (2021)
Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
Sazan Rasul et al.
CANCERS (2021)
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
Florian Rosar et al.
CANCERS (2021)
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
Liam Widjaja et al.
CANCERS (2021)
Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
Judith Stangl-Kremser et al.
EUROPEAN UROLOGY OPEN SCIENCE (2021)
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
Sazan Rasul et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
Marat Gallyamov et al.
CLINICAL KIDNEY JOURNAL (2020)
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Sazan Rasul et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Johanna Maffey-Steffan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase
Hendrik Rathke et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
Madhav Prasad Yadav et al.
CLINICAL NUCLEAR MEDICINE (2020)
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
Robert Seifert et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Radiation Dosimetry in Lu-177-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
Price A. Jackson et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients
Giovanni Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Influence of short-term dexamethasone on the efficacy of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Thorsten Derlin et al.
PROSTATE (2020)
Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study
Thorsten Derlin et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
Moran Gadot et al.
CANCERS (2020)
A Retrospective Analysis of the Safety and Activity of Lutetium-177-PSMA Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer
Raya Leibowitz et al.
ONCOLOGIST (2020)
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
Andrei Gafita et al.
EUROPEAN UROLOGY (2020)
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Andreas Rinscheid et al.
EJNMMI PHYSICS (2020)
Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer
Theresa Ida Goetz et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2020)
Improving quality of life in patients with metastatic prostate cancer following one cycle of(177)Lu-PSMA-617 radioligand therapy: a pilot study
Milka Marinova et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2020)
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
Majid Assadi et al.
WORLD JOURNAL OF NUCLEAR MEDICINE (2020)
Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
Sandra Barna et al.
CLINICAL NUCLEAR MEDICINE (2020)
Modeling and Predicting Tumor Response in Radioligand Therapy
Peter Kletting et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression
Louise Emmett et al.
CLINICAL GENITOURINARY CANCER (2019)
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT
Hendrik Rathke et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
Martin K. Bakht et al.
ENDOCRINE-RELATED CANCER (2019)
68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Alexander Heinzel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
Thomas W. Barber et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol
Anna Sarnelli et al.
MOLECULES (2019)
Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution
Rhiannon McBean et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2019)
The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival
Emine Acar et al.
ANNALS OF NUCLEAR MEDICINE (2019)
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
Ludwike van Kalmthout et al.
CLINICAL NUCLEAR MEDICINE (2019)
Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
Jingnan Wang et al.
CLINICAL NUCLEAR MEDICINE (2019)
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Alec Paschalis et al.
EUROPEAN UROLOGY (2019)
3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT
Astrid Gosewisch et al.
EJNMMI RESEARCH (2019)
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Bernhard Grubmueller et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Anna Yordanova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
Matthias M. Heck et al.
EUROPEAN UROLOGY (2019)
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort
Sonam Suman et al.
BRITISH JOURNAL OF RADIOLOGY (2019)
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia - A prospective study
Ramin Akbarian Aghdam et al.
WORLD JOURNAL OF NUCLEAR MEDICINE (2019)
Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status
Manoj Gupta et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617
Katharina Kessel et al.
THERANOSTICS (2019)
Delayed response after repeated Lu-177-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Kambiz Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
K. Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Hendrik Rathke et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice
Murali Kesavan et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2018)
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma
Ambreen Khawar et al.
CLINICAL NUCLEAR MEDICINE (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0
Andrew T. Taylor et al.
SEMINARS IN NUCLEAR MEDICINE (2018)
Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
Zain Khurshid et al.
Oncotarget (2018)
Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
Astrid Gosewisch et al.
EJNMMI RESEARCH (2018)
Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
Christian Filss et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2018)
Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Shozo Okamoto et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
Justin Ferdinandus et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
Wolfgang P. Fendler et al.
ONCOTARGET (2017)
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
Lorenza Scarpa et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Braeuer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Hojjat Ahmadzadehfar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer
Madhav P. Yadav et al.
NUCLEAR MEDICINE COMMUNICATIONS (2017)
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2017)
Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2017)
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry
Levent Kabasakal et al.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY (2017)
Dosimetry for Lu-177-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
Andreas Delker et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
Richard P. Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
Melanie Hohberg et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer
Levent Kabasakal et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
Hojjat Ahmadzadehfar et al.
EJNMMI RESEARCH (2015)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
Sebastian Mannweiler et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)